



# Activation of the mGlu<sub>1</sub> metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M<sub>4</sub> muscarinic receptor allosteric modulators

Samantha E. Yohn<sup>1,2</sup> · Daniel J. Foster<sup>1,2,3</sup> · Dan P. Covey<sup>4</sup> · Mark S. Moehle<sup>1,2</sup> · Jordan Galbraith<sup>1</sup> · Pedro M. Garcia-Barrantes<sup>5</sup> · Hyekyung P. Cho<sup>2</sup> · Michael Bubser<sup>1,2</sup> · Anna L. Blobaum<sup>2</sup> · Max E. Joffe<sup>1,2</sup> · Joseph F. Cheer<sup>4,6</sup> · Carrie K. Jones<sup>1,2,3</sup> · Craig W. Lindsley<sup>1,2,5</sup> · P. Jeffrey Conn<sup>1,2,3</sup>

Received: 29 December 2017 / Revised: 1 June 2018 / Accepted: 28 June 2018 / Published online: 16 August 2018  
© Springer Nature Limited 2018

## Abstract

Recent clinical and preclinical studies suggest that selective activators of the M<sub>4</sub> muscarinic acetylcholine receptor have potential as a novel treatment for schizophrenia. M<sub>4</sub> activation inhibits striatal dopamine release by mobilizing endocannabinoids, providing a mechanism for local effects on dopamine signaling in the striatum but not in extrastriatal areas. G protein-coupled receptors (GPCRs) typically induce endocannabinoid release through activation of G<sub>α<sub>q/11</sub></sub>-type G proteins whereas M<sub>4</sub> transduction occurs through G<sub>α<sub>i/o</sub></sub>-type G proteins. We now report that the ability of M<sub>4</sub> to inhibit dopamine release and induce antipsychotic-like effects in animal models is dependent on co-activation of the G<sub>α<sub>q/11</sub></sub>-coupled mGlu<sub>1</sub> subtype of metabotropic glutamate (mGlu) receptor. This is especially interesting in light of recent findings that multiple loss of function single nucleotide polymorphisms (SNPs) in the human gene encoding mGlu<sub>1</sub> (*GRM1*) are associated with schizophrenia, and points to *GRM1*/mGlu<sub>1</sub> as a gene within the “druggable genome” that could be targeted for the treatment of schizophrenia. Herein, we report that potentiation of mGlu<sub>1</sub> signaling following thalamo-striatal stimulation is sufficient to inhibit striatal dopamine release, and that a novel mGlu<sub>1</sub> positive allosteric modulator (PAM) exerts robust antipsychotic-like effects through an endocannabinoid-dependent mechanism. However, unlike M<sub>4</sub>, mGlu<sub>1</sub> does not directly inhibit dopamine D<sub>1</sub> receptor signaling and does not reduce motivational responding. Taken together, these findings highlight a novel mechanism of cross talk between mGlu<sub>1</sub> and M<sub>4</sub> and demonstrate that highly selective mGlu<sub>1</sub> PAMs may provide a novel strategy for the treatment of positive symptoms associated with schizophrenia.

**Electronic supplementary material** The online version of this article (<https://doi.org/10.1038/s41380-018-0206-2>) contains supplementary material, which is available to authorized users.

✉ P. Jeffrey Conn  
Jeff.Conn@Vanderbilt.edu

<sup>1</sup> Department of Pharmacology, Vanderbilt University, Nashville, TN, USA

<sup>2</sup> Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, TN, USA

<sup>3</sup> Vanderbilt Kennedy Center, Vanderbilt University School of Medicine, Nashville, TN, USA

<sup>4</sup> Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, USA

<sup>5</sup> Department of Chemistry, Department of Biochemistry, Vanderbilt University, Nashville, TN, USA

<sup>6</sup> Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA

## Introduction

Currently approved antipsychotics are efficacious in treating positive symptoms of schizophrenia in many patients, however they offer little to no benefit for negative or cognitive symptoms, and are associated with a number of adverse effects [1, 2]. Thus, there is a critical need to develop fundamentally new approaches for treating schizophrenia that provide improved efficacy and induce fewer adverse effects than current medications.

In recent years, intense translational efforts suggest that highly selective positive allosteric modulators (PAMs) of the M<sub>4</sub> muscarinic acetylcholine receptor (mAChR) may provide a novel approach for the treatment of schizophrenia. Most notably, a four-week, double-blind, placebo-controlled outcome trial revealed that an M<sub>1</sub>/M<sub>4</sub> subtype-preferring mAChR agonist, xanomeline, produced statistically significant improvements in total Positive and

Negative Syndrome Scale (PANSS) in schizophrenia patients, as well as trends toward improvements in the PANSS positive and negative subscales, and specific domains of cognitive function [3]. Furthermore, xanomeline displays efficacy in animal models that predict clinical efficacy across these three symptom domains [4–6]. Interestingly, the antipsychotic-like effects of xanomeline are absent in M<sub>4</sub> knockout mice [7] and mimicked by administration of highly selective M<sub>4</sub> PAMs [8–11], suggesting that some of the antipsychotic-like effects of xanomeline are mediated by M<sub>4</sub> activation. Finally, genetic studies reveal that single nucleotide polymorphisms (SNPs) of *CHRM4*, the gene encoding M<sub>4</sub>, were associated with an increased risk of developing schizophrenia [12].

Hyperactivity in subcortical dopamine (DA) signaling contributes to the manifestation of positive symptoms in schizophrenia [13, 14] and imaging studies suggest that schizophrenia patients' display selective increases in DA release in the dorsal striatum, with decreases in extrastriatal DA release [15]. Interestingly, detailed preclinical, cellular, genetic, and optogenetic studies reveal that M<sub>4</sub> PAMs inhibit DA release in the dorsolateral striatum (DLS) by specific actions on M<sub>4</sub> in a subpopulation of spiny projection neurons (SPNs) that express D<sub>1</sub>-DA receptors (D<sub>1</sub>-SPNs) [11]. Activation of M<sub>4</sub> on D<sub>1</sub>-SPNs induces an inhibition of DA release that is dependent upon both synthesis of the endocannabinoid (eCB) 2-arachidonoylglycerol (2-AG) and activation of CB<sub>2</sub> receptors located on neighboring DA terminals [11]. The mobilization of 2-AG by M<sub>4</sub> provides a novel mechanism that allows local inhibition of DA signaling in striatal regions that are most critical for positive symptoms of schizophrenia, without inhibiting DA in other regions where DA signaling is already impaired. However, despite this promising profile, activation of M<sub>4</sub> also directly inhibits D<sub>1</sub> signaling in D<sub>1</sub>-SPNs through activation of G $\alpha_{i/o}$ -type G proteins, which inhibits D<sub>1</sub> receptor-mediated activation of adenylyl cyclase [16]. Therefore, M<sub>4</sub> activation could excessively inhibit D<sub>1</sub> relative to D<sub>2</sub> DA receptor signaling, rather than maintaining balanced inhibition of both D<sub>1</sub> and D<sub>2</sub>-dependent signaling pathways.

The finding that M<sub>4</sub> activation inhibits DA release through stimulation of 2-AG was somewhat surprising in light of studies showing that G protein-coupled receptors (GPCRs) typically induce eCB release by activation of G $\alpha_{q/11}$  and induction of intracellular calcium (Ca<sup>++</sup>) [17, 18]. M<sub>4</sub> signals through G $\alpha_{i/o}$  and does not couple to G $\alpha_{q/11}$  or induce Ca<sup>++</sup> mobilization in SPNs [11]. This raises the possibility that M<sub>4</sub>-induced release of 2-AG and inhibition of DA release may require co-activation of another GPCR that activates G $\alpha_{q/11}$  and facilitates Ca<sup>++</sup> mobilization. If so, this G $\alpha_{q/11}$ -coupled GPCR could provide a

novel target that may be more proximal to eCB synthesis and inhibition of DA release, and may inhibit DA release without altering the balance between D<sub>1</sub> and D<sub>2</sub> signaling pathways.

Based on previous studies, the group I metabotropic glutamate (mGlu) receptors (mGlu<sub>1</sub> and Glu<sub>5</sub>), are prime candidates as G $\alpha_{q/11}$ -coupled GPCRs that may interact with M<sub>4</sub> and inhibit DA release through eCB signaling. Group I mGlu receptors are heavily expressed in striatal SPNs [19, 20], where they couple to G $\alpha_{q/11}$  and their signal transduction pathway induces Ca<sup>++</sup> mobilization [21–23] and activates eCB signaling [24]. Furthermore, multiple loss of function SNPs in the human gene encoding mGlu<sub>1</sub> (*GRM1*) are associated with schizophrenia [25, 26], suggesting that mGlu<sub>1</sub> may play a key role in modulating schizophrenia-related circuitry. We now report a series of studies using ex vivo and in vivo cyclic voltammetry, along with genetic and optogenetic approaches, to show that activation of mGlu<sub>1</sub> is critical for M<sub>4</sub>-induced reductions in DA release and antipsychotic-like effects in animal models. Furthermore, synaptic or agonist-induced activation of mGlu<sub>1</sub> is sufficient to inhibit DA release and a highly selective mGlu<sub>1</sub> PAM induces robust antipsychotic-like effects, which are dependent on eCB signaling. Interestingly, unlike M<sub>4</sub>, mGlu<sub>1</sub> activation does not directly inhibit DA D<sub>1</sub> signaling and does not reduce motivational responding. Collectively, these findings provide strong evidence that mGlu<sub>1</sub> PAMs have robust antipsychotic efficacy and highlight the mGlu<sub>1</sub> receptor as an exciting novel target for the treatment of positive symptoms associated with schizophrenia.


## Materials and methods

### Animals

Adult, drug-naive, C57BL/6J mice (Jackson Laboratory; 6–10 weeks old) and CB<sub>2</sub> knockout (KO) mice (Jackson Laboratory; 005786; 8–10 weeks old) were kept on a 12 h light/dark cycle and were tested during the light phase (lights on at 7:00 h). All experiments were approved by the Institutional Animal Care and Use Committee, Vanderbilt University. Detailed materials and methods are provided as Supplementary Information. All efforts were made to minimize the number of animals while maintaining statistical rigor.

### Ex vivo fast scan cyclic voltammetry

Striatal DA release was measured as described previously [11] (See Supplemental Methods).



**Fig. 1** Activation of mGlu<sub>1</sub> is Required for M<sub>4</sub>-induced Reductions in Striatal DA Release and Subsequent Antipsychotic-like Effects. **a–c** Time courses of 30  $\mu$ M Oxo-M-induced inhibition of electrically-evoked striatal DA release alone or in the presence of either 3  $\mu$ M of the mGlu<sub>5</sub> negative allosteric modulator (NAM), MTEP, or the mGlu<sub>1</sub> NAM VU0469650 (VU'650). All time-course data are depicted as mean  $\pm$  SEM. **d** Boxplot summaries depicting the percent inhibition of striatal DA release observed under different conditions at peak time points ( $n = 6–8$ ; \*significant from 30  $\mu$ M Oxo-M;  $p < 0.05$ ; one way ANOVA with Dunnett's multiple comparison posthoc test). **e** Total locomotor activity of area under the curve (AUC) in wildtype (WT) C57BL/6J mice following administration of 4 mg/kg amphetamine (AMP; s.c.),

1 mg/kg VU0467154 (VU'154; i.p.), and 60 mg/kg VU0469650 (VU'650; i.p.;  $n = 9–12$ ; \* $p < 0.05$ , significant difference from AMP/VEH condition; \*\*\* $p < 0.001$  significant difference from AMP/VEH condition; one-way ANOVA with Dunnett's multiple comparison posthoc test). Total locomotor counts are depicted as the mean  $\pm$  SEM. **f** Averaged data showing percent prepulse inhibition (PPI) observed in WT mice following administration of vehicle (VEH; 10% Tween 80), 4 mg/kg amphetamine (AMP), 10 mg/kg VU0467154 (VU'154), and 60 mg/kg VU0469650 (VU'650;  $n = 15–20$ ; \* $p < 0.05$ , significant difference from AMP/VU'154 condition; \*\* $p < 0.01$ , significant difference from AMP/VU'154 condition; one-way ANOVA with Dunnett's multiple comparison posthoc test). PPI data are depicted as the mean  $\pm$  SEM

## Whole-cell patch clamp

Slice preparation and recordings were conducted using procedures previously described [16] (See Supplemental Methods).

## In vivo fast scan cyclic voltammetry

Mice were anesthetized and immobilized in a stereotaxic apparatus as described previously [27] (See Supplemental Methods). In sum, a twisted, bipolar, stimulating electrode was implanted into the medial forebrain bundle (MFB; mm from bregma, AP: -1.1, ML:  $\pm$  1.4; DV - 3.3) and a carbon fiber working electrode into the dorsal striatum (DLS; mm from bregma, AP: + 1.3; ML:  $\pm$  2.3, DV: -2.7). Biphasic current pulse ( $\pm$  450  $\mu$ A, 60 Hz, 4 ms pulse width) were applied for 2 s to the DA axons in the MFB to evoke DA release in the DLS following administration of vehicle (10% Tween 80, intraperitoneal injection (i.p.)) or the mGlu<sub>1</sub> PAM VU6004909 (60 mg/kg, i.p.). Sufficient time (i.e., five minutes) was allowed between stimulations for evoked responses to recover.

## Microdialysis

Guide cannulae were implanted into the medial prefrontal cortex (mPFC) and were collected as described previously [10] (see Supplemental Methods). DA in dialysate samples were analyzed by the Vanderbilt University Neurochemistry Core using liquid chromatography (LC)-mass spectrometry. Only animals with accurate probe placement that showed three consecutive stable baseline values (within  $\leq$  20%) were included in the statistical analysis. Prior to analysis, samples (5  $\mu$ L) were derivatized with benzoyl chloride [28]. LC was performed on a 2.0  $\times$  50 mm, 1.7  $\mu$ M particle Acquity BEH C18 column (Waters Corporation, Milford, MA, USA) using a Waters Acquity UPLC. Mobile phase A was 15% aqueous formic acid and mobile phase B was acetonitrile. Samples were separated by a gradient of 98–5% of mobile phase A over 11 min at a flow rate of 0.6 mL/min prior to delivery to a SCIEX 6500 + QTrap mass spectrometer (AB Sciex LLC, Framingham, MA, USA). Chromatograms were analyzed using MultiQuant 3.0.2 Software from SCIEX.

## Behavioral tests

Tests for locomotor activity [29], prepulse inhibition (PPI) of the acoustic startle reflex [30], motivated behavior [31], rotarod and TreadScan were conducted, as previously described and outlined in supplemental materials. Randomizations were performed for counter-balanced behavioral assays by alternating mice based on mouse number.

Rotarod and TreadScan measures were measured and recorded by a blinded investigator. All other behavioral data was collected by MedAssociates software.

## Statistics


When appropriate, data are represented as the mean  $\pm$  SEM. Statistical analyses were performed using two-tailed Student's *t*-test, one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparison post hoc test and two-way ANOVA followed by Bonferroni's post hoc test, as described in the figure legends. Samples sizes are indicated in figure legends. A value of  $p < 0.05$  was considered as statistically significant. All comparisons met the assumptions of the test used, including similar variance between groups being compared. Post hoc power analyses ensured a sufficient number of slices and mice were used.

## Results

### mGlu<sub>1</sub> activation is required for M<sub>4</sub>-induced reductions in striatal DA release and antipsychotic-like effects

Due to the localization of group I mGlu receptors in D<sub>1</sub>-SPNs [19, 20, 32] and their well-defined role in modulating SPNs via eCB production [33, 34], we tested the hypothesis that M<sub>4</sub>-induced reductions in DA release require co-activation of group I mGlu receptors. The effect of the muscarinic acetylcholine receptor (mAChR) agonist oxotremorine-M (Oxo-M) on electrically-evoked DA release in striatal slices was assessed using fast-scan cyclic voltammetry (FSCV) in the absence or presence of selective negative allosteric modulators (NAMs) of individual group I mGlu receptor subtypes. All studies were performed in the presence of the nicotinic acetylcholine receptor antagonist dihydro- $\beta$ -erythroidine hydrobromide (DH $\beta$ E, 1  $\mu$ M). Consistent with previous studies [11], 30  $\mu$ M Oxo-M induced a sustained M<sub>4</sub>-mediated inhibition of DA release (Fig. 1a, d). This effect of Oxo-M on DA release was not blocked by the selective mGlu<sub>5</sub> NAM, MTEP (3  $\mu$ M) (Fig. 1b, d), but was significantly attenuated by application of an mGlu<sub>1</sub> NAM VU0469650 (3  $\mu$ M) (46.7%  $\pm$  9.02 in the absence and 21.37%  $\pm$  3.14 in the presence of VU0469650; one-way ANOVA,  $p < 0.05$ ; Fig. 1c, d), suggesting that the M<sub>4</sub>-mediated reduction in DA release is dependent upon mGlu<sub>1</sub> activation. Consistent with this, VU0469650 also blocked the inhibition of DA release observed following application of the M<sub>4</sub> PAM VU0467154 (rat M<sub>4</sub> EC<sub>50</sub> = 17.7 nM, inactive at rat M<sub>1,2,3,5</sub>) [9] with a submaximal concentration of Oxo-M (10  $\mu$ M) (52%  $\pm$  6.07 in the absence and 9.13%  $\pm$





2.72 in the presence of VU0469650; students *t*-test,  $p < 0.01$ ; Supplementary Fig. 1A, B).

M<sub>4</sub> PAMs have robust efficacy in multiple animal models of antipsychotic activity, including an ability to

attenuate amphetamine-induced hyperlocomotion (AHL) and disruption of pre-pulse inhibition (PPI) [8–10], and these effects are thought to be mediated, at least in part, by inhibition of DA release. Thus, we examined the ability of

◀ **Fig. 2** mGlu<sub>1</sub>-mediates DHPG induced Reductions in Striatal DA Release and Requires CB<sub>2</sub> Receptor Activation. **a** Time course of a concentration response curve of 10 and 30 μM DHPG, a group I mGlu receptor agonist, in the presence of the nAChR antagonist DhβE on electrically evoked striatal DA release. **b** Before and after graphs of peak effects of either 10 or 30 μM DHPG on DA release compared to baseline (BL) conditions ( $n = 6-8$ ;  $***p < 0.001$  significant difference from BL; students *t*-test). **c** Time courses of 30 μM DHPG in the presence of either 3 μM of the mGlu<sub>5</sub> NAM, MTEP, or the mGlu<sub>1</sub> NAM VU0469650 (VU'650). **d** Boxplot summaries of peak effects of 30 μM DHPG following blockade of mGlu<sub>5</sub> or mGlu<sub>1</sub> receptors ( $n = 6-10$ ;  $**p < 0.01$ , significant difference from 30 μM DHPG; one-way ANOVA with Dunnett's multiple comparison posthoc test). **e** Time course of 10 μM DHPG in the presence of 3 μM VU6004909 (VU'4909). **f** Boxplot summaries of peak effects of 10 μM DHPG alone or in combination with 3 μM mGlu<sub>1</sub> PAM VU6004909 (VU'4909;  $n = 6-8$ ;  $**p < 0.01$ , significant difference from 10 μM DHPG; students *t*-test). **g** Boxplot summaries of peak effects of 30 μM DHPG alone or in the presence of 3 μM AM251, CB<sub>1</sub> antagonist, or 3 μM AM630, CB<sub>2</sub> antagonist, on striatal DA release ( $n = 6-10$ ;  $***p < 0.001$ , significant difference from 30 μM DHPG; one-way ANOVA with Dunnett's multiple comparison posthoc test). **h** Time courses of 30 μM DHPG in wildtype (WT; blue) or CB<sub>2</sub> knockout mice (KO; black)

mGlu<sub>1</sub> blockade to blunt the efficacy of M<sub>4</sub> PAMs on AHL and PPI. Consistent with previous findings [9–11], VU0467154 (1 mg/kg, intraperitoneal (i.p.)), reversed AHL (Fig. 1e; one-way ANOVA,  $p < 0.001$ ) and VU0467154 (10 mg/kg) attenuated amphetamine-induced deficits in PPI (Fig. 1f; one-way ANOVA,  $p < 0.01$ ). Interestingly, the effects of the M<sub>4</sub> PAM on AHL (one-way ANOVA,  $p < 0.05$ ; Fig. 1e) and PPI (one-way ANOVA,  $p < 0.01$ ; Fig. 1f) were attenuated by prior administration of the mGlu<sub>1</sub> NAM, VU0469650 (60 mg/kg). In both AHL and PPI, all treatment conditions had similar baseline activity counts (data not shown) and acoustic startle responses were not altered by dosing with amphetamine, VU0467154 or VU0469650 alone or in combination (data not shown). Finally, the effects of M<sub>1</sub>/M<sub>4</sub> preferring agonist xanomeline on AHL were also partially attenuated by prior administration of the mGlu<sub>1</sub> NAM, VU0469650 (60 mg/kg) (one-way ANOVA,  $p < 0.05$ ; Supplemental Fig. 1C, D). Taken together, these findings suggest that mGlu<sub>1</sub> is a critical modulator of the antipsychotic-like effects of M<sub>4</sub> activation.

### Activation of mGlu<sub>1</sub> reduces striatal DA release via activation of CB<sub>2</sub> cannabinoid receptors


Previous studies suggest that a non-selective agonist of group I mGlu receptors can inhibit striatal DA release [35]. This raises the possibility that mGlu<sub>1</sub> may not only be required for M<sub>4</sub> PAMs to inhibit DA release, but may be capable of inducing this response in the absence M<sub>4</sub> agonists. We now report that application of 30 μM DHPG, a group I mGlu receptor agonist, induces a robust inhibition of DA release compared to baseline ( $25.415\% \pm 5.856$  and

$-2.576\% \pm 1.106$ , respectively; students paired *t*-test,  $p < 0.001$ ; Fig. 2a, b) and this response was completely blocked by the mGlu<sub>1</sub> NAM VU0469650 (3 μM) but not by the mGlu<sub>5</sub> NAM MTEP (3 μM) (Fig. 2c, d; one-way ANOVA,  $p < 0.01$ ). These results suggest that DHPG-induced reductions in striatal DA release are mediated by mGlu<sub>1</sub> activation. To further evaluate the potential role of mGlu<sub>1</sub> on DA release, we determined the effects of two selective mGlu<sub>1</sub> PAMs, Ro-07-11401 [36] and VU6004909 (rat mGlu<sub>1</sub> EC<sub>50</sub> = 31 nM, inactive at mGlu<sub>2,3,5,7,8</sub>; EC<sub>50</sub> > 10 μM at mGlu<sub>4</sub>) [37], on a subthreshold concentration of DHPG (10 μM). In contrast to 30 μM DHPG, application of 10 μM DHPG alone did not produce a significant inhibition in striatal DA release (students *t*-test,  $p > 0.05$ ; Fig. 2a, b). However, this concentration of DHPG induced a robust inhibition of DA release when co-applied with either 3 μM Ro-07-11401 ( $12.180 \pm 3.229$ ; students *t*-test,  $p < 0.01$ ; Supplemental Fig. 2A, B) or 3 μM VU6004909 ( $22.748 \pm 7.519$ ; students *t*-test,  $p < 0.01$ ; Fig. 2e, f). Collectively, these results suggest that activation of mGlu<sub>1</sub> inhibits stimulus-induced DA release in the striatum.

Activation of mGlu<sub>1</sub> generates diacylglycerol, which is converted to 2-AG by the Ca<sup>++</sup>-dependent enzyme diacylglycerol lipase (DAGL) [38, 39], raising the possibility that mGlu<sub>1</sub>-mediated reductions in DA release are similar to M<sub>4</sub>-mediated effects in that they are mediated by eCB mobilization and activation of CB<sub>2</sub> receptors [11]. Consistent with this, inhibition of CB<sub>2</sub> receptors via the CB<sub>2</sub> antagonist AM630 (3 μM) significantly blocked DHPG-induced inhibition of DA release (one-way ANOVA,  $p < 0.001$ , Fig. 2g; Supplemental Fig. 2C). Furthermore, the effects of DHPG were absent in slices from CB<sub>2</sub> knockout (KO) mice (Fig. 2h; Supplemental Fig. 2D), confirming a critical role for the CB<sub>2</sub> receptor in mediating this response. In contrast to the CB<sub>2</sub> receptor antagonist, bath application of 3 μM AM251, a CB<sub>1</sub> antagonist, did not significantly attenuate 30 μM DHPG-induced reductions in striatal DA release (one-way ANOVA,  $p > 0.05$ , Fig. 2g; Supplemental Fig. 2C).

### mGlu<sub>1</sub> activation following stimulation of thalamostriatal afferents attenuates striatal DA release

The striatum receives extensive glutamatergic innervation from the cortex [40] and several thalamic nuclei [41]. Both afferent inputs have been reported to modulate striatal DA release [35, 42, 43], however, it is critical to determine whether activation of mGlu<sub>1</sub> by these glutamatergic inputs inhibits DA release, and whether this response is specific to either cortico-striatal or thalamo-striatal synapses. To test the hypothesis that endogenous glutamate acts on mGlu<sub>1</sub> to inhibit DA release, we selectively activated corticostriatal or



**Fig. 3** Activation of  $mGlu_1$  following Stimulation of Thalamostriatal Afferents modulates Striatal DA Release. **a** Schematic of viral injection strategy to target glutamatergic afferents from the paraventricular nucleus (PVT) of the thalamus to the dorsal lateral striatum (DLS). **b** Time course depicting the effect of 3 Hz optical stimulation of thalamic inputs (black) on electrically-evoked striatal DA release, an effect that is blocked following application of the  $mGlu_1$  NAM VU0469650 (VU'650; red). **c** Boxplot summary depicting the percent inhibition of DA release at the peak time point following stimulation of thalamostriatal afferents ( $n = 12-16$ ,  $**p < 0.01$ , significant

difference from peak inhibition of optical stimulation; students  $t$ -test). **d** Schematic of viral injection strategy to target glutamatergic afferents from the motor cortex (M1) to the dorsal lateral striatum (DLS). **e** Time course depicting the effect of 3 Hz optical stimulation of cortical inputs to the striatum (black) on electrically-evoked striatal DA release, an effect that is not blocked following application of the  $mGlu_1$  NAM VU0469650 (VU'650; red). **f** Boxplot summary depicting the percent inhibition of DA release at the peak time point following stimulation corticostriatal afferents ( $n = 12-16$ ; not significantly different, students  $t$ -test  $p > 0.05$ )

thalamostriatal axons in the striatum by virally expressing ChR2-eYFP in the motor cortex (M1) or the paraventricular nucleus of the thalamus (PVT; Fig. 3a, d). In coronal sections containing ChR2-eYFP expression, we recorded electrically evoked DA in the presence of  $1 \mu\text{M}$  DH $\beta$ E prior to, during, and following optical stimulation (3 Hz, 12.5 min). Stimulation of thalamostriatal afferents produced a 15% inhibition in striatal DA release (Fig. 3b, c), which returned to baseline after terminating optical stimulation.

The  $mGlu_1$  NAM VU0469650 ( $3 \mu\text{M}$ ) attenuated thalamostriatal induced reductions in DA release (students  $t$ -test;  $p < 0.01$ ; Fig. 3b, c), whereas antagonists of ionotropic glutamate (iGluRs) and  $mGlu_5$  receptors did not inhibit this response (Supplemental Fig. 3A, B). Interestingly, selective activation of corticostriatal afferents produced a 27% sustained inhibition in striatal DA release, but this response was not inhibited by the  $mGlu_1$  NAM VU0469650 (Fig. 3e, f). The reduction in striatal DA release observed following

corticostriatal stimulation was eliminated by incubation with a cocktail of antagonists for other glutamate receptors (Supplemental Fig. 3C, D). Taken together, these findings suggest that mGlu<sub>1</sub> inhibits striatal DA release in an input-specific manner and regulates DA release by glutamate from thalamostriatal but not corticostriatal afferents.

### The mGlu<sub>1</sub> PAM, VU6004909, reduces dorsolateral striatal DA release in vivo and displays antipsychotic efficacy

The finding that mGlu<sub>1</sub> activation inhibits striatal DA release raises the possibility that selective mGlu<sub>1</sub> PAMs could reduce DA release in vivo and have antipsychotic-like effects. To determine whether a selective mGlu<sub>1</sub> PAM [37] reduces striatal DA release, we examined the effects of systemic administration of VU6004909 using FSCV in isoflurane anesthetized mice. DA release was monitored in the dorsolateral striatum (DLS) following electrical stimulation of the medial forebrain bundle (MFB) in animals treated with either vehicle (10% Tween 80) or 60 mg/kg VU6004909 (Fig. 4a–c). Compared to vehicle, VU6004909 significantly reduced striatal DA release 40 min after administration (Fig. 4b), which corresponds to the  $T_{\max}$  for this compound [37]. The averaged peak effect, observed 60 minutes after administration, was statistically significant from vehicle-control conditions (students *t*-test,  $p < 0.01$ ; Fig. 4c). These results confirm our *ex vivo* voltammetry studies and indicate that administration of the mGlu<sub>1</sub> PAM can reduce striatal DA release in vivo.

Next, we assessed the ability of VU6004909 to exert antipsychotic-like activity in rodent models that are dependent on increased DA transmission and are known to be responsive to antipsychotic agents and M<sub>4</sub> PAMs. Consistent with previous studies [11, 44], amphetamine (4 mg/kg, *s.c.*) induced a robust decrease in PPI (one-way ANOVA,  $p < 0.001$ ), an effect that was dose-dependently reversed by pretreatment with 30 mg/kg ( $p < 0.05$ ) or 60 mg/kg VU6004909 (one-way ANOVA,  $p < 0.01$ ; Fig. 4d). The highest dose of VU6004909 (60 mg/kg, *i.p.*) alone had no effect on PPI compared to vehicle ( $1409.42 \pm 102.21$  and  $1164.19 \pm 81.16$ , respectively; Supplemental Fig. 4A).

Amphetamine (4 mg/kg, *s.c.*) also produced a significant increase in locomotor activity, and this effect was attenuated by administration of 60 mg/kg VU6004909 (students *t*-test,  $p < 0.01$ ; Fig. 4e; Supplemental Fig. 4B). Acute treatment with VU6004909 (60 mg/kg) alone induced a slight, but statistically significant reduction in total spontaneous locomotor activity compared to vehicle-treated animals (students *t*-test,  $p < 0.05$ ; Supplemental Fig. 5A, B) but was without effect on cerebellum-dependent motor tasks, such as the rotarod and TreadScan (Supplemental Fig. 5C, D–F,


respectively). Interestingly, the ability of VU6004909 to attenuate amphetamine disruptions in PPI (one-way ANOVA,  $p < 0.05$ ; Supplemental Fig. 6C) and AHL (one-way ANOVA,  $p < 0.05$ ; Supplemental Fig. 6A, B) were absent following systemic administration of a CB<sub>2</sub> antagonist (AM630). Administration of AM630 alone did not affect basal levels of locomotion or disrupt the startle response (Supplemental Fig. 6A, D, respectively). Together, these findings demonstrate that VU6004909 exerts antipsychotic-like effects, and these effects are dependent on CB<sub>2</sub> activation.

### mGlu<sub>1</sub> does not directly inhibit signaling at the DA D<sub>1</sub> receptor and does not impair motivation

In addition to inhibiting DA release, we recently reported that M<sub>4</sub> PAMs directly inhibit D<sub>1</sub>-mediated increases in GABA-mediated synaptic responses in terminals of D<sub>1</sub>-SPNs in the substantia nigra pars reticulata (SNr), through G $\alpha_{i/o}$ -dependent inhibition of cAMP formation [16]. Based on these findings, M<sub>4</sub> could induce an excessive inhibition of D<sub>1</sub> relative to D<sub>2</sub> signaling. D<sub>1</sub> plays a critical role in regulating motor function, cognition, and motivation [16, 45–48], therefore a mechanism that maintains balance of D<sub>1</sub>/D<sub>2</sub> signaling may be preferable for the treatment of schizophrenia [49–51]. Since mGlu<sub>1</sub> primarily couples to G $\alpha_{q/11}$  rather than G $\alpha_{i/o}$ , we would not expect mGlu<sub>1</sub> PAMs to directly inhibit D<sub>1</sub> signaling in SNr SPN terminals. To test this hypothesis, we performed whole-cell patch clamp recordings from GABAergic cells of the SNr and assessed the effects of an mGlu<sub>1</sub> PAM on miniature inhibitory post synaptic currents (mIPSCs). As previously reported [16], the D<sub>1</sub> agonist SKF82958 (10  $\mu$ M) induced a leftward shift in mIPSC cumulative probability plots with a ~40% increase in mIPSC frequency compared to baseline (Supplemental Fig. 7A–C). In contrast to effects of M<sub>4</sub> PAMs [16], pretreatment with the mGlu<sub>1</sub> PAM VU6004909 (3 or 10  $\mu$ M) did not attenuate the effect of SKF82958 on mIPSCs (Supplemental Fig. 7A–C), suggesting that mGlu<sub>1</sub> activation does not inhibit effects of D<sub>1</sub> agonists on mIPSC frequency. Furthermore, in contrast to M<sub>4</sub> PAMs [16], VU6004909 did not attenuate SKF82958 (1 mg/kg, *i.p.*) induced increases in locomotor activity (Supplemental Fig. 7D, E) (students *t*-test,  $p > 0.05$ ). Taken together, these results suggest that mGlu<sub>1</sub> PAMs do not directly inhibit effects of direct-acting D<sub>1</sub>-receptor agonists.

Since reductions in DA D<sub>1</sub> signaling have been implicated in reduced motivation [48, 52, 53], we determined the effects of the mGlu<sub>1</sub> PAM (VU6004909), M<sub>4</sub> PAM (VU0467154), and the typical antipsychotic haloperidol on motivational responding in a traditional progressive ratio (PR) schedule [31], where rodents need to nose poke for a 30% Strawberry Ensure solution (Fig. 5a). We assessed






**Fig. 4** The Novel mGlu<sub>1</sub> PAM VU6004909 Reduces Striatal DA Release in vivo and Displays Antipsychotic Efficacy. **a** Color plots from a representative vehicle (10% Tween 80) and 60 mg/kg VU6004909 (VU'4909) treated animal; potential is on the y-axis plotted against time on the x-axis and the current response is represented in false color. **b** Time course of striatal DA release following i. p. administration of VEH or PAM ( $n = 6-8$ ;  $*p < 0.05$ , significant difference between VEH and PAM at the time sampled; two-way factorial ANOVA with posthoc sample *t*-test). All time-course data are depicted as mean  $\pm$  SEM. **c** Averaged DA inhibition at baseline (BL) and 60 minutes post administration ( $n = 6-8$ ;  $**p < 0.01$ , significant difference between PAM BL and 60 minutes after administration;

students *t*-test). **d** Averaged data showing percent prepulse inhibition (PPI) observed in wildtype (WT) mice following administration of vehicle (VEH; 10% Tween 80), 4 mg/kg amphetamine (AMP; s.c.), and various doses of VU6004909 (VU'4909; 10, 30, 60 mg/kg; i.p.) plus AMP ( $n = 15-20$ ;  $*p < 0.05$ , significant difference from AMP/VEH condition;  $**p < 0.01$ , significant difference from AMP/VEH condition;  $***p < 0.001$ , significant difference from AMP/VEH condition one-way ANOVA with Dunnett's multiple comparison posthoc test). **e** Total locomotor activity of area under the curve (AUC) in wildtype (WT) mice following administration of 4 mg/kg amphetamine (AMP) and 60 mg/kg VU6004909 (VU'4909;  $n = 14$ ;  $**p < 0.01$ , significant difference from AMP/VEH condition; students *t*-test)

motivation as total number of pokes and highest ratio achieved. Consistent with prior reports [54], administration of haloperidol (0.2 mg/kg, i.p.), a dose that possesses antipsychotic efficacy following amphetamine challenges (data not shown) significantly decreased total pokes and highest

ratio achieved (repeated measures ANOVA,  $p < 0.001$ ; Fig. 5b, c). While a low dose of the M<sub>4</sub> PAM VU0467154 (0.3 mg/kg) did not have effects on responding in this model, a higher dose (3.0 mg/kg), significantly reduced total pokes and highest ratio achieved compared to vehicle



**Fig. 5** Effects of mGlu<sub>1</sub> Activation on Progressive Ratio Performance and Ventral Striatal DA Release. **a** Schematic of the progressive ratio (PR) assay, where mice are required to nose poke for 30% Ensure reward. Mean (±SEM) number of total nose pokes (**b**) and highest ratio achieved (**c**). **d** Total amount of ensure consumed in a free feeding session (in grams; \*\**p* < 0.001, significant difference from

VEH conditions; repeated measures ANOVA with Dunnett's multiple comparison posthoc test; *n* = 12–24). **e** Time course of 30 μM DHPG in the presence of 5 μM MTEP, mGlu<sub>5</sub> NAM, and 1 μM DhβE on ventral striatal DA release. **f** Averaged ventral striatal DA release at baseline (BL) and following application of MTEP and DhβE to isolate mGlu<sub>1</sub> specific effects (*n* = 8; students *t*-test *p* > 0.05)

(repeated measures ANOVA, *p* < 0.001). These reductions in motivation are not due to an appetite suppressant effect (repeated measures ANOVA, *p* > 0.05; Fig. 5d) or reduction in spontaneous locomotion (students *t*-test, *p* > 0.05; data

not shown), but rather the work requirements of the task. Interestingly 30 and 60 mg/kg VU6004909, doses that attenuate deficits in AHL and PPI, did not affect motivation (Fig. 5b, c).

Reductions in operant responding have been correlated with reduced levels of DA in the ventral striatum [55] and with the manifestation of negative symptoms, including motivational deficits [53, 56]; therefore, we assessed mGlu<sub>1</sub> activation on ventral striatum DA release. To test this, we performed *ex vivo* FSCV and isolated mGlu<sub>1</sub> via bath application of the nACh antagonist DhβE (1 μM) and the mGlu<sub>5</sub> NAM MTEP (5 μM), and recorded changes in DA release in the nucleus accumbens (NAc) following application of 30 μM DHPG. Interestingly, in contrast to its effects in DLS, activation of mGlu<sub>1</sub> does not produce a significant change in NAc DA release compared to baseline (Fig. 5e, f; paired students *t*-test,  $p > 0.05$ ). Furthermore, since some negative symptoms and cognitive disturbances in schizophrenia patients are associated with aberrant frontal lobe function [57, 58] and reduced DA levels in the prefrontal cortex (PFC) [59], we examined DA levels following mGlu<sub>1</sub> activation in the PFC through both *ex vivo* FSCV (Supplemental Fig. 8A) and microdialysis. Our FSCV data demonstrates that activation of mGlu<sub>1</sub> produced a slight rise, although not statistically significant from baseline, in PFC DA release (Supplemental Fig. 8B; students *t*-test,  $p > 0.05$ ). Moreover, data collected from microdialysis, with probes implanted in the infralimbic or prelimbic PFC (Supplemental Fig. 8C), revealed that similar to *ex vivo* DA recordings, systemic administration of the mGlu<sub>1</sub> PAM VU6004909 did not produce a significant change compared to vehicle-control nor a significant sample  $\times$  treatment interaction (two-way ANOVA,  $p > 0.05$ ) in PFC DA levels (Supplemental Fig. 8D). However, there was a significant effect of time (two-way ANOVA,  $p < 0.05$ ), suggesting that DA in both treatment groups increased relative to baseline levels. Taken together, these findings suggest that by its self, activation of mGlu<sub>1</sub> does not affect extracellular DA in the PFC.

## Discussion

Several clinical and preclinical studies suggest that dysfunction at glutamatergic synapses may play a critical role in the pathophysiological changes that underlie schizophrenia [60–63]. However, specific changes in glutamate signaling that contribute to symptoms in different subpopulations of schizophrenia patients are not well understood. Interestingly, recent genetic studies identified multiple nonsynonymous SNPs in the human gene encoding mGlu<sub>1</sub> (*GRM1*) that are associated with schizophrenia [26, 64]. Furthermore, we reported that these mutations lead to deficits in mGlu<sub>1</sub> signaling [25, 26], raising the possibility that disrupted signaling of mGlu<sub>1</sub> could contribute to the symptoms of schizophrenia in some patients. However, the

roles of mGlu<sub>1</sub> in brain circuits that are disrupted in schizophrenia patients are not understood.

Here, we show that activation of mGlu<sub>1</sub> through application of exogenous agonists or selective stimulation of thalamostriatal afferents induces a robust inhibition of DA release in the dorsolateral striatum and that selective mGlu<sub>1</sub> PAMs exert antipsychotic-like effects in rodent models. These findings are consistent with previous studies showing that mGlu receptor agonists reduce striatal DA release [34], mGlu<sub>1</sub> KO mice have altered locomotor responses to amphetamine [65] and with anatomical studies suggesting that mGlu<sub>1</sub> is preferentially expressed at thalamostriatal synapses [66]. Our data are especially interesting in light of a large body of studies suggesting that striatal dopaminergic hyperactivity is associated with psychotic symptoms in schizophrenic patients [15, 67, 68] and that excessive striatal DA predicts treatment response to current antipsychotics [69]. Furthermore, we have previously shown that mGlu<sub>1</sub> PAMs reverse deficits in mGlu<sub>1</sub> signaling observed with schizophrenia-associated mutations [25]. Taken together, these data raise the possibility that selective mGlu<sub>1</sub> PAMs may provide a novel approach to treatment of positive symptoms both in a broad schizophrenia patient population, as well as in schizophrenia patients with *GRM1* mutations.

Interestingly, our studies also suggest that mGlu<sub>1</sub> activation is required for M<sub>4</sub> PAM-induced inhibition of DA release and antipsychotic-like effects. M<sub>4</sub> PAMs have received increasing attention as a novel approach to treatment of schizophrenia, and clinical studies suggest that mAChR agonists have efficacy in schizophrenia patients [3]. Thus, the present findings provide a mechanistic link between mGlu<sub>1</sub> PAMs, and two clinically validated targets (muscarinic agonists and DA receptor antagonists). However, in contrast to available antipsychotic agents, the present results and previous studies [11] suggest that mGlu<sub>1</sub> and M<sub>4</sub> PAMs reduce DA signaling through local release of an eCB from striatal SPNs and activation of CB<sub>2</sub> receptors on neighboring DA terminals. Interestingly, tonic eCB signaling does not appear to play a key role in DA release; however, when eCBs are mobilized by an mGlu<sub>1</sub> PAM a CB<sub>2</sub> antagonist can block these effects. These local effects are interesting in the light of recent clinical imaging studies suggesting that the symptoms in schizophrenia patients are associated with selective increases in striatal DA signaling while extrastriatal regions display hypo-dopaminergic function [70, 71]. Thus, mGlu<sub>1</sub> and M<sub>4</sub> PAMs may provide a mechanism for selective inhibition of DA release in striatal regions that are important for antipsychotic efficacy, without further disruptions in extrastriatal DA signaling.

While these studies suggest that the effects of M<sub>4</sub> PAMs on DA release require activation of mGlu<sub>1</sub>, we have also found that these targets have important differences. Most

notably, M<sub>4</sub> PAMs also directly inhibit D<sub>1</sub> signaling in D<sub>1</sub>-SPN terminals in the SNr and this effect likely regulates M<sub>4</sub>-dependent actions on locomotor activity [16]. In contrast, we found that mGlu<sub>1</sub> activation does not inhibit D<sub>1</sub>/cAMP-mediated increases in transmission at GABAergic synapses of striatal D<sub>1</sub>-SPNs and that mGlu<sub>1</sub> PAMs do not suppress D<sub>1</sub> agonist-induced increases in locomotor activity. While the relative importance of these different actions of M<sub>4</sub> PAMs is not entirely clear, the finding that mGlu<sub>1</sub> PAMs do not inhibit D<sub>1</sub> signaling through actions that are independent of DA release could provide therapeutic benefits over traditional antipsychotics and M<sub>4</sub> PAMs. Most notably, current antipsychotics [56, 72], as well as D<sub>1</sub> antagonists [48] reduce motivation, as well as ventral striatal and PFC DA release. Consistent with this, we found that therapeutically relevant doses of a typical antipsychotic, haloperidol, or an M<sub>4</sub> PAM significantly reduce motivational responding in a progressive ratio operant paradigm. Interestingly, low doses of M<sub>4</sub> PAMs do not impair motivated behavior but do possess antipsychotic-efficacy, suggesting that it is possible to provide efficacy for the positive symptom domain without inducing or worsening negative symptoms. In contrast, efficacious doses of an mGlu<sub>1</sub> PAM did not impair motivated performance or alter DA release in the ventral striatum. It is possible that differential effects of these agents on D<sub>1</sub> signaling and distinct actions in other brain regions, such as the PFC or ventral striatum, contribute to their different effects on motivational responding. The mesolimbic DA system and interconnected forebrain regions are a critical component of brain circuitry that regulate behavioral activation and motivated behavior [73, 74] and it will be important in the future to fully evaluate the effects of mGlu<sub>1</sub> and M<sub>4</sub> PAMs as compared to currently available antipsychotics in regions that may be important for motivated behavior.

In addition to modulating motivated behavior, DA release in the striatum and PFC are heavily implicated in the manifestation of negative symptoms in schizophrenia. Accordingly, future studies are needed to explore the efficacy of mGlu<sub>1</sub> PAMs on the negative symptoms, such as preclinical models of NMDA hypofunction, which are thought to recapitulate all symptom clusters. Previous studies have shown that M<sub>4</sub> PAMs display robust efficacy following challenge with an NMDA antagonist, such as MK801 [9]. Therefore, it will be of interest to compare the effects of mGlu<sub>1</sub> PAMs in these preclinical models to those observed following M<sub>4</sub> administration.

In conclusion, we present a series of studies that build upon extensive preclinical mechanistic and drug discovery efforts, as well as human genetics, imaging, and clinical intervention studies, that raise the possibility, that mGlu<sub>1</sub> PAMs may provide a novel approach for the treatment of the positive symptoms of schizophrenia. Future studies are

needed to evaluate the therapeutic potential of mGlu<sub>1</sub> PAMs on negative and cognitive symptom domains. It will be important to develop a more complete understanding of the actions of mGlu<sub>1</sub> PAMs in disease relevant models as well as the impact of specific *GRM1* mutations on identified circuits that have been implicated in schizophrenia.

**Acknowledgements** We would like to thank Douglas Shaw and Ginger Milne for their invaluable assistance. This work was supported by funding from an NIH Institutional Training Grant (T32 MH065215-14) and Ruth L. Kirschstein National Research Service Award (F32MH113266) to SEY, a NARSAD Young Investigator Award to DJF, grants to PJC from National Institute of Mental Health (MH062646) and the National Institute of Neurological Disease and Stroke (NS031373), National Institute on Drug Abuse grants to JFC (DA022340 and DA042595) and a NARSA to DPC (DA041827). Research conducted by the Vanderbilt Neurochemistry Core is supported by the EKS NICHD of the NIH (U54HD083211). Data generated by the Neurochemistry Core is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

**Author contributions:** SEY and PJC conceived the studies and wrote the manuscript. SEY, DJF, DPC, MSM, CKJ, JFC, and MB designed experiments. SEY, DPC, MSM, JG, ALB, HPC, and MB conducted experiments and analyzed the data. CWL and PMBG provided pharmacological tools utilized in this study.

**Competing interests** CWL and PJC are inventors on patents that protect different classes of metabotropic glutamate allosteric modulators. CWL has been funded by the NIH, Johnson and Johnson, Bristol-Myers Squibb, AstraZeneca, Michael J. Fox Foundation, as well as Seaside Therapeutics. He has consulted for AbbVie and received compensation. PJC has been funded by NIH, AstraZeneca, Bristol-Myers Squibb, Michael J. Fox Foundation, Dystonia Medical Research Foundation, CHDI Foundation, and Thome Memorial Foundation. Over the past three years he has served on the Scientific Advisory Boards for Michael J. Fox Foundation, Stanley Center for Psychiatric Research Broad Institute, Karuna Pharmaceuticals, Lieber Institute for Brain Development, Clinical Mechanism and Proof of Concept Consortium, and Neurobiology Foundation for Schizophrenia and Bipolar Disorder. SEY, DJF, DPC, MSM, JG, PMGB, HPC, MB, ALB, MEJ, JFC, and CKJ declare no potential conflicts of interest.

## References

1. Strange PG. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. *Pharmacol Rev.* 2001;53:119–33.
2. Kaiser R, Tremblay PB, Klufmoller F, Roots I, Brockmoller J. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia. *Mol Psychiatry.* 2002;7:695–705.
3. Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dube S, Mallinckrodt C, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. *Am J Psychiatry.* 2008;165:1033–9.
4. Barak S, Weiner I. The M(1)/M(4) preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia. *Int J Neuropsychopharmacol.* 2011;14:1233–46.



5. Shannon HE, Rasmussen K, Bymaster FP, Hart JC, Peters SC, Swedberg MD, et al. Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. *Schizophr Res.* 2000;42:249–59.
6. Stanhope KJ, Mirza NR, Bickerdike MJ, Bright JL, Harrington NR, Hesselink MB, et al. The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. *J Pharmacol Exp Ther.* 2001;299:782–92.
7. Woolley ML, Carter HJ, Gartlon JE, Watson JM, Dawson LA. Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice. *Eur J Pharmacol.* 2009;603:147–9.
8. Brady AE, Jones CK, Bridges TM, Kennedy JP, Thompson AD, Heiman JU, et al. Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. *J Pharmacol Exp Ther.* 2008;327:941–53.
9. Bubser M, Bridges TM, Dencker D, Gould RW, Grannan M, Noetzel MJ, et al. Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents. *ACS Chem Neurosci.* 2014;5:920–42.
10. Byun NE, Grannan M, Bubser M, Barry RL, Thompson A, Rosanelli J, et al. Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100. *Neuropsychopharmacology.* 2014;39:1578–93.
11. Foster DJ, Wilson JM, Remke DH, Mahmood MS, Uddin MJ, Wess J, et al. Antipsychotic-like effects of M4 positive allosteric modulators are mediated by CB2 receptor-dependent inhibition of dopamine release. *Neuron.* 2016;91:1244–52.
12. Scarr E, Um JY, Cowie TF, Dean B. Cholinergic muscarinic M4 receptor gene polymorphisms: a potential risk factor and pharmacogenomic marker for schizophrenia. *Schizophr Res.* 2013;146:279–84.
13. Brisch R, Saniotis A, Wolf R, Bielau H, Bernstein HG, Steiner J, et al. The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. *Front Psychiatry.* 2014;5:47.
14. Nishi A, Shuto T. Potential for targeting dopamine/DARPP-32 signaling in neuropsychiatric and neurodegenerative disorders. *Expert Opin Ther Targets.* 2017;21:259–72.
15. Weinstein JJ, Chohan MO, Slifstein M, Kegeles LS, Moore H, Abi-Dargham A. Pathway-specific dopamine abnormalities in schizophrenia. *Biol Psychiatry.* 2017;81:31–42.
16. Moehle MS, Pancani T, Byun N, Yohn SE, Willison GH, Dickerson JW, et al. Cholinergic projections to the substantia nigra reticulata inhibit dopamine modulation of basal ganglia through the M4 muscarinic receptor. *Neuron.* 2017;96:1358–72.
17. Gyombolai P, Pap D, Turu G, Catt KJ, Bagdy G, Hunyady L. Regulation of endocannabinoid release by G proteins: a paracrine mechanism of G protein-coupled receptor action. *Mol Cell Endocrinol.* 2012;353:29–36.
18. Szekeres M, Nadasy GL, Turu G, Soltesz-Katona E, Benyo Z, Offermanns S, et al. Endocannabinoid-mediated modulation of Gq/11 protein-coupled receptor signaling-induced vasoconstriction and hypertension. *Mol Cell Endocrinol.* 2015;403:46–56.
19. Testa CM, Standaert DG, Young AB, Penney JB Jr. Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. *J Neurosci.* 1994;14:3005–18.
20. Kerner JA, Standaert DG, Penney JB Jr., Young AB, Landwehrmeyer GB. Expression of group one metabotropic glutamate receptor subunit mRNAs in neurochemically identified neurons in the rat neostriatum, neocortex, and hippocampus. *Brain Res Mol Brain Res.* 1997;48:259–69.
21. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. *Physiol Rev.* 2003;83:1017–66.
22. Hashimoto Y, Ohno-Shosaku T, Tsubokawa H, Ogata H, Emoto K, Maejima T, et al. Phospholipase C $\beta$  serves as a coincidence detector through its Ca $^{2+}$  dependency for triggering retrograde endocannabinoid signal. *Neuron.* 2005;45:257–68.
23. Turu G, Hunyady L. Signal transduction of the CB1 cannabinoid receptor. *Mol Cell Endocrinol.* 2010;44:75–85.
24. Niswender CM, Conn PJ. Metabotropic glutamate receptors: physiology, pharmacology, and disease. *Annu Rev Pharmacol Toxicol.* 2010;50:295–322.
25. Cho HP, Garcia-Barrantes PM, Brogan JT, Hopkins CR, Niswender CM, Rodriguez AL, et al. Chemical modulation of mutant mGlu1 receptors derived from deleterious GRM1 mutations found in schizophrenics. *ACS Chem Biol.* 2014;9:2334–46.
26. Ayoub MA, Angelicheva D, Vile D, Chandler D, Morar B, Cavanaugh JA, et al. Deleterious GRM1 mutations in schizophrenia. *PLoS ONE.* 2012;7:e32849.
27. Covey DP, Juliano SA, Garris PA. Amphetamine elicits opposing actions on readily releasable and reserve pools for dopamine. *PLoS ONE.* 2013;8:e60763.
28. Wong JM, Malec PA, Mabrouk OS, Ro J, Dus M, Kennedy RT. Benzoyl chloride derivatization with liquid chromatography-mass spectrometry for targeted metabolomics of neurochemicals in biological samples. *J Chromatogr A.* 2016;1446:78–90.
29. Seibenhener ML, Wooten MC. Use of the Open Field Maze to measure locomotor and anxiety-like behavior in mice. *JoVE.* 2015;96:e52434.
30. Valsamis B, Schmid S. Habituation and prepulse inhibition of acoustic startle in rodents. *JoVE.* 2011;55:e3446.
31. Wilson AN, Gratz OH. Using a progressive ratio schedule of reinforcement as an assessment tool to inform treatment. *Behav Anal Pract.* 2016;9:257–60.
32. Tallaksen-Greene SJ, Kaatz KW, Romano C, Albin RL. Localization of mGluR1a-like immunoreactivity and mGluR5-like immunoreactivity in identified populations of striatal neurons. *Brain Res.* 1998;780:210–7.
33. Luscher C, Huber KM. Group 1 mGluR-dependent synaptic long-term depression: mechanisms and implications for circuitry and disease. *Neuron.* 2010;65:445–59.
34. Yin HH, Davis MI, Ronesi JA, Lovinger DM. The role of protein synthesis in striatal long-term depression. *J Neurosci.* 2006;26:11811–20.
35. Zhang H, Sulzer D. Glutamate spillover in the striatum depresses dopaminergic transmission by activating group 1 metabotropic glutamate receptors. *J Neurosci.* 2003;23:10585–92.
36. Garcia-Barrantes PM, Cho HP, Starr TM, Blobaum AL, Niswender CM, Conn PJ, et al. Re-exploration of the mGlu(1) PAM Ro 07-11401 scaffold: Discovery of analogs with improved CNS penetration despite steep SAR. *Bioorg Med Chem Lett.* 2016;26:2289–92.
37. Garcia-Barrantes PM, Cho HP, Metts AM, Blobaum AL, Niswender CM, Conn PJ, et al. Lead optimization of the VU0486321 series of mGlu(1) PAMs. Part 2: SAR of alternative 3-methyl heterocycles and progress towards an in vivo tool. *Bioorg Med Chem Lett.* 2016;26:751–6.
38. Maejima T, Oka S, Hashimoto Y, Ohno-Shosaku T, Aiba A, Wu D, et al. Synaptically driven endocannabinoid release requires Ca $^{2+}$ -assisted metabotropic glutamate receptor subtype 1 to phospholipase C $\beta$ 4 signaling cascade in the cerebellum. *J Neurosci.* 2005;25:6826–35.
39. Marcaggi P, Attwell D. Endocannabinoid signaling depends on the spatial pattern of synapse activation. *Nat Neurosci.* 2005;8:776–81.

40. Zheng T, Wilson CJ. Corticostriatal combinatorics: the implications of corticostriatal axonal arborizations. *J Neurophysiol*. 2002;87:1007–17.
41. Smith Y, Raju DV, Pare JF, Sidibe M. The thalamostriatal system: a highly specific network of the basal ganglia circuitry. *Trends Neurosci*. 2004;27:520–7.
42. Kosillo P, Zhang YF, Threlfell S, Cragg SJ. Cortical control of striatal dopamine transmission via striatal cholinergic interneurons. *Cereb Cortex*. 2016;26:4160–9.
43. Morari M, Marti M, Sbrenna S, Fuxe K, Bianchi C, Beani L. Reciprocal dopamine-glutamate modulation of release in the basal ganglia. *Neurochem Int*. 1998;33:383–97.
44. van den Buuse M. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. *Schizophr Bull*. 2010;36:246–70.
45. Roffman JL, Tanner AS, Eryilmaz H, Rodriguez-Thompson A, Silverstein NJ, Ho NF, et al. Dopamine D1 signaling organizes network dynamics underlying working memory. *Sci Adv*. 2016;2:e1501672.
46. Centonze D, Grande C, Saulle E, Martin AB, Gubellini P, Pavon N, et al. Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity. *J Neurosci*. 2003;23:8506–12.
47. Chiken S, Sato A, Ohta C, Kurokawa M, Arai S, Maeshima J, et al. Dopamine D1 receptor-mediated transmission maintains information flow through the cortico-striato-entopeduncular direct pathway to release movements. *Cereb Cortex*. 2015;25:4885–97.
48. Yohn SE, Santerre JL, Nunes EJ, Kozak R, Podurgiel SJ, Correa M, et al. The role of dopamine D1 receptor transmission in effort-related choice behavior: Effects of D1 agonists. *Pharmacol Biochem Behav*. 2015;135:217–26.
49. Cazorla M, Kang UJ, Kellendonk C. Balancing the basal ganglia circuitry: a possible new role for dopamine D2 receptors in health and disease. *Mov Disord*. 2015;30:895–903.
50. Avery MC, Krichmar JL. Improper activation of D1 and D2 receptors leads to excess noise in prefrontal cortex. *Front Comput Neurosci*. 2015;9:31.
51. Horga G, Cassidy CM, Xu X, Moore H, Slifstein M, Van Snellenberg JX, et al. Dopamine-related disruption of functional topography of striatal connections in unmedicated patients with schizophrenia. *JAMA Psychiatry*. 2016;73:862–70.
52. Abi-Dargham A. Probing cortical dopamine function in schizophrenia: what can D1 receptors tell us? *World Psychiatry*. 2003;2:166–71.
53. Wolf DH, Satterthwaite TD, Kantrowitz JJ, Katchmar N, Vandekar L, Elliott MA, et al. Amotivation in schizophrenia: integrated assessment with behavioral, clinical, and imaging measures. *Schizophr Bull*. 2014;40:1328–37.
54. Olarte-Sanchez CM, Valencia-Torres L, Cassaday HJ, Bradshaw CM, Szabadi E. Effects of SKF-83566 and haloperidol on performance on progressive ratio schedules maintained by sucrose and corn oil reinforcement: quantitative analysis using a new model derived from the Mathematical Principles of Reinforcement (MPR). *Psychopharmacology*. 2013;230:617–30.
55. Salamone JD, Correa M, Mingote S, Weber SM. Nucleus accumbens dopamine and the regulation of effort in food-seeking behavior: implications for studies of natural motivation, psychiatry, and drug abuse. *J Pharmacol Exp Ther*. 2003;305:1–8.
56. Strauss GP, Whearty KM, Morra LF, Sullivan SK, Ossenfort KL, Frost KH. Avolition in schizophrenia is associated with reduced willingness to expend effort for reward on a Progressive Ratio task. *Schizophr Res*. 2016;170:198–204.
57. Ziauddeen H, Dibben C, Kipps C, Hodges JR, McKenna PJ. Negative schizophrenic symptoms and the frontal lobe syndrome: one and the same. *Eur Arch Psychiatry Clin Neurosci*. 2011;261:59–67.
58. Wible CG, Anderson J, Shenton ME, Kricun A, Hirayasu Y, Tanaka S, et al. Prefrontal cortex, negative symptoms, and schizophrenia: an MRI study. *Psychiatry Res*. 2001;108:65–78.
59. Patel NH, Vyas NS, Puri BK, Nijran KS, Al-Nahhas A. Positron emission tomography in schizophrenia: a new perspective. *J Nucl Med*. 2010;51:511–20.
60. Farber NB, Newcomer JW, Olney JW. The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease. *Prog Brain Res*. 1998;116:421–37.
61. Field JR, Walker AG, Conn PJ. Targeting glutamate synapses in schizophrenia. *Trends Mol Med*. 2011;17:689–98.
62. Coyle JT, Basu A, Benneyworth M, Balu D, Konopaske G. Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. *Handb Exp Pharmacol*. 2012;213:267–95.
63. Rubio MD, Drummond JB, Meador-Woodruff JH. Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments. *Biomol Ther*. 2012;20:1–18.
64. Pietraszek M, Nagel J, Gravius A, Schafer D, Danysz W. The role of group I metabotropic glutamate receptors in schizophrenia. *Amino Acids*. 2007;32:173–8.
65. Mao L, Conquet F, Wang JQ. Augmented motor activity and reduced striatal preprodynorphin mRNA induction in response to acute amphetamine administration in metabotropic glutamate receptor 1 knockout mice. *Neuroscience*. 2001;106:303–12.
66. Paquet M, Smith Y. Group I metabotropic glutamate receptors in the monkey striatum: subsynaptic association with glutamatergic and dopaminergic afferents. *J Neurosci*. 2003;23:7659–69.
67. Brunelin J, Fecteau S, Suaud-Chagny MF. Abnormal striatal dopamine transmission in schizophrenia. *Curr Med Chem*. 2013;20:397–404.
68. Kegeles LS, Abi-Dargham A, Frankle WG, Gil R, Cooper TB, Slifstein M, et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. *Arch Gen Psychiatry*. 2010;67:231–9.
69. Abi-Dargham A, van de Giessen E, Slifstein M, Kegeles LS, Laruelle M. Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. *Biol Psychiatry*. 2009;65:1091–3.
70. Slifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R, et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. *JAMA Psychiatry*. 2015;72:316–24.
71. Kambertz J, Abi-Dargham A, Kapur S, Howes OD. Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies. *Br J Psychiatry*. 2014;204:420–9.
72. Gold JM, Strauss GP, Waltz JA, Robinson BM, Brown JK, Frank MJ. Negative symptoms of schizophrenia are associated with abnormal effort-cost computations. *Biol Psychiatry*. 2013;74:130–6.
73. Salamone JD, Correa M, Yohn S, Lopez Cruz L, San Miguel N, Alatorre L. The pharmacology of effort-related choice behavior: Dopamine, depression, and individual differences. *Behav Process*. 2016;127:3–17.
74. Salamone JD, Koychev I, Correa M, McGuire P. Neurobiological basis of motivational deficits in psychopathology. *Eur Neuropsychopharmacol*. 2015;25:1225–38.
75. Covey DP, Danrassy HM, Zlebnik NE, Gildish I, Cheer JF. Compromised dopaminergic encoding of reward accompanying suppressed willingness to overcome high effort costs is a prominent prodromal characteristic of the Q175 mouse model of Huntington's Disease. *J Neurosci*. 2016;36:4993–5002.
76. Michael D, Travis ER, Wightman RM. Color images for fast-scan CV measurements in biological systems. *Anal Chem*. 1998;70:586A–92A.